Pfizer: Dedicated science team seeks external partners

“What gets our interest is solid science, a realistic and appropriate representation of the science being proposed and of the conclusions. When we look through the briefs, we often see lots of claims with little data, and it is rare to see significant data with few claims. Yet it is going to be the data that need to be convincing,” says Pfizer’s Uwe Schoenbeck. Read more »